Marshall Edwards, Inc. to Present at the UBS Global Life Sciences Conference
September 18 2006 - 9:54AM
PR Newswire (US)
NEW YORK, Sept. 18 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc.
(NASDAQ:MSHL) will present at the UBS Global Life Sciences
Conference at the Grand Hyatt in New York on Monday September 25th
2006 at 12 noon. The presentation will be simultaneously audio
webcast and can be accessed on the website http://www.ibb.ubs.com/.
About Marshall Edwards, Inc. Marshall Edwards, Inc. (NASDAQ:MSHL)
has licensed rights from Novogen Limited (NASDAQ:NVGN) to bring
three oncology drugs -- phenoxodiol, NV-196 and NV-143 -- to market
globally. Marshall Edwards, Inc. is majority owned by Novogen, an
Australian biotechnology company that is specializing in the
development of therapeutics based on regulation of the
sphingomyelin pathway. Novogen, based in Sydney, Australia, is
developing a range of therapeutics across the fields of oncology,
cardiovascular disease and inflammatory diseases. More information
on phenoxodiol and on the Novogen group of companies can be found
at http://www.marshalledwardsinc.com/ and http://www.novogen.com/.
Under U.S. law, a new drug cannot be marketed until it has been
investigated in clinical trials and approved by the FDA as being
safe and effective for the intended use. Statements included in
this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe
harbor" provisions of the Private Securities Litigation Reform Act
of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements,
which are based on management's current expectations and are
subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product
candidates; costs and delays in the development and/or FDA
approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability
to maintain or enter into, and the risks resulting from our
dependence upon, collaboration or contractual arrangements
necessary for the development, manufacture, commercialization,
marketing, sales and distribution of any products; competitive
factors; our inability to protect our patents or proprietary rights
and obtain necessary rights to third party patents and intellectual
property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to
gain market acceptance; our inability to obtain any additional
required financing; technological changes; government regulation;
changes in industry practice; and one-time events. We do not intend
to update any of these factors or to publicly announce the results
of any revisions to these forward-looking statements. DATASOURCE:
Marshall Edwards, Inc. CONTACT: David Sheon, +1-202-518-6321, , for
Marshall Edwards, Inc. Web site: http://www.marshalledwardsinc.com/
http://www.novogen.com/ http://www.ibb.ubs.com/
Copyright
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024